Posts in the “Non Small Cell Lung Cancer Non Small Cell Lung Cancer” category:

Lung Cancer Trials Soften Endpoint

Posted by Samantha Powell on March 3rd, 2014 |

taille hollister femme News Headline: Lung Cancer Trials Soften Endpoint Date: 3/3/14 Outlet Full Name: Med Page Today Author: Charles Bankhead http://www.medpagetoday.com/HematologyOncology/LungCancer/44584 Use of overall survival as the primary endpoint has decreased significantly in clinical trials of advanced lung cancer, as has the magnitude of clinically relevant improvement, a review of 200 studies showed. Before […]

Added Benefit of Afatnib Depends on Mutation Status in Non-Small Cell Lung Cancer

Posted by Samantha Powell on February 21st, 2014 |

News Headline: Added Benefit of Afatnib Depends on Mutation Status in Non-Small Cell Lung Cancer Date: 2/21/14 Outlet Full Name: Medical News Today Author: No author http://www.medicalnewstoday.com/releases/272932.php Lung cancer patients with Del19 mutation benefit most Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally […]

Chemotherapy Questions Linger in Early NSCLC

Posted by Samantha Powell on September 23rd, 2013 |

News Headline: Chemotherapy Questions Linger in Early NSCLC Date: 9/23/13 Outlet Full Name: OncLive Author Name: Anita T. Shaffer http://www.onclive.com/publications/Oncology-live/2013/September-2013/Chemotherapy-Questions-Linger-in-Early-NSCLC The optimal use of adjuvant chemotherapy for patients with early-stage non-small cell lung cancer (NSCLC) remains unresolved, with several clinical trials under way in Europe aimed at identifying ways to better select patients for treatment, […]

NCI Awards Insight Genetics $1.5M to Further Develop NSCLC Assay

Posted by Samantha Powell on August 26th, 2013 |

News Headline: NCI Awards Insight Genetics $1.5M to Further Develop NSCLC Assay Date: 8/26/13 Outlet Full Name: GenomeWeb Daily News Author Name: N/A http://www.genomeweb.com/pcrsample-prep/nci-awards-insight-genetics-15m-further-develop-nsclc-assay NEW YORK (GenomeWeb News) – Insight Genetics today announced it was awarded a $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute to continue development of […]

Pemetrexed maintenance therapy improved OS in non–small cell lung cancer

Posted by Samantha Powell on August 1st, 2013 |

Date: 8/1/2013 Outlet Full Name: Healio Patients with non–small cell lung cancer who received pemetrexed maintenance therapy experienced significantly longer OS than those who received placebo, according to results of the phase 3 PARAMOUNT study. The trial included 939 patients with advanced nonsquamous NSCLC who received four cycles of an induction therapy of pemetrexed (Alimta, […]

Research Adds a New Acronym to the List of Lung Cancer Targets

Posted by Samantha Powell on July 30th, 2013 |

Date: 7/30/2013 Outlet Full Name: Science Life Author Name: Matt Wood Oncologists used to divide lung cancer into two types: small-cell and non-small cell. But as genetic research uncovered more mutations that cause lung cancer, non-small cell lung cancer has been subdivided further into an alphabet soup of acronyms: EML4-ALK translocations, ROS1 translocations or KRAS […]

Personalizing lung cancer care through biomarker testing

Posted by Samantha Powell on July 29th, 2013 |

Date: 7/29/2013 Outlet Full Name: Journal Sentinel The concept of personalized medicine – matching a patient’s unique genetic profile with an appropriate and more individualized treatment plan – is transforming the care of patients with cancer. Over the last decade, the scientific community has gained a greater understanding of genetic mutations, or abnormalities, associated with […]

FDA Approves New Drug for Advanced Lung Cancer

Posted by Samantha Powell on July 12th, 2013 |

Date: 7/12/13 Outlet Full Name: Doctors Lounge Author Name: N/A Gilotrif targets a gene mutation that occurs in about 10 percent of cases. FRIDAY, July 12 (HealthDay News) — A new drug to treat advanced lung cancer has been approved by the U.S. Food and Drug Administration. Gilotrif (afatinib) is approved to treat patients with […]

Boehringer Wins U.S. Approval for Targeted Lung Cancer Drug

Posted by Samantha Powell on July 12th, 2013 |

Date: 7/12/13 Outlet Full Name: Bloomberg Businessweek Author Name: Anna Edney Boehringer Ingelheim GmbH, the German family owned drugmaker, won U.S. approval for a lung cancer therapy to be used with a Qiagen NV (QGEN:US) gene test that pinpoints patients who will best respond to the medication. The Food and Drug Administration in a statement […]

UT Dallas Study Suggests New Approach to Fighting Lung Cancer

Posted by Samantha Powell on June 20th, 2013 |

Recent research has shown that cancer cells have a much different – and more complex – metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer. In an article published online May 21 in the journal PLOS […]